VACH
Voyager Acquisition Corp Class A Ordinary SharesVACH
VACH
About: Voyager Acquisition Corp is a blank check company.
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.64% more ownership
Funds ownership: 79.21% [Q4 2024] → 81.85% (+2.64%) [Q1 2025]
5% more capital invested
Capital invested by funds: $201M [Q4 2024] → $211M (+$9.87M) [Q1 2025]
9% less funds holding
Funds holding: 45 [Q4 2024] → 41 (-4) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for VACH.
Financial journalist opinion
Based on 3 articles about VACH published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors

Neutral
GlobeNewsWire
2 weeks ago
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors

Neutral
GlobeNewsWire
3 weeks ago
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies

Charts implemented using Lightweight Charts™